ReNeuron Group plc Block Listing Review and Total Voting Rights (1143Y)
March 01 2017 - 2:00AM
UK Regulatory
TIDMRENE
RNS Number : 1143Y
ReNeuron Group plc
01 March 2017
1 March 2017 AIM: RENE
ReNeuron Group plc
("ReNeuron" or "the Company")
Block Listing Review and Total Voting Rights
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, provides the following
update in accordance with Schedule Six of the AIM Rules for
Companies regarding its existing block listing arrangements:
Name: ReNeuron Group plc
----------------------------------- -----------------------
Name of Scheme: ReNeuron Share Option
Schemes
----------------------------------- -----------------------
Period of Return: From 22 September 2016
to 28 February 2017
----------------------------------- -----------------------
Balance of unallotted 90,282,511 Ordinary
securities under scheme(s) Shares (of 1p each)
from previous return:
----------------------------------- -----------------------
Plus: The amount by N/A
which the block scheme(s)
has been increased
since the date of the
last Review (if any
increase has been applied
for):
----------------------------------- -----------------------
Less: Number of securities
issued/allotted under N/A
scheme(s) during period
----------------------------------- -----------------------
Equals: Balance under 90,282,511 Ordinary
scheme(s) not yet issued/allotted Shares
at end of period:
----------------------------------- -----------------------
Number and class of 2,000,000 Ordinary
securities originally Shares on 13 May 2010
admitted and the date
of admission:
----------------------------------- -----------------------
Total Voting Rights
The Company has 3,164,618,541 ordinary shares in issue, all with
voting rights. The Company holds no ordinary shares in treasury.
The figure of 3,164,618,541 Ordinary Shares may be used by
shareholders as the denominator for the calculation by which they
will determine if they are required to notify their interest in, or
a change in their interest in, the Company under the FCA's
Disclosure and Transparency Rules.
ENDS
ENQUIRIES:
ReNeuron +44 (0)20 3819 8400
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan +44 (0) 20 7466 5000
Mark Court, Sophie Cowles, Stephanie Watson
Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Broker)
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development
company. Based in the UK, its primary objective is the development
of novel cell-based therapies targeting areas of significant unmet
or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop
cell-based therapies for significant disease conditions where the
cells can be readily administered "off-the-shelf" to any eligible
patient without the need for additional immunosuppressive drug
treatments. The Company has therapeutic candidates in clinical
development for motor disability as a result of stroke, for
critical limb ischaemia and for the blindness-causing disease,
retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential new nanomedicine targeting cancer and as a
potential delivery system for gene therapy treatments.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. Further information on ReNeuron and its products can
be found at www.reneuron.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCOKFDNABKDFBB
(END) Dow Jones Newswires
March 01, 2017 02:00 ET (07:00 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2023 to Apr 2024